Impact of Cannabis Use on Least Pain Scores Among African American and White Patients with Cancer Pain: A Moderation Analysis
Salimah H Meghani,Ryan Quinn,Rebecca Ashare,Kristin Levoy,Brooke Worster,Mary Naylor,Jesse Chittams,Martin Cheatle
DOI: https://doi.org/10.2147/JPR.S332447
IF: 2.8319
2021-11-06
Journal of Pain Research
Abstract:Salimah H Meghani, 1, 2 Ryan Quinn, 1 Rebecca Ashare, 3, 4 Kristin Levoy, 1, 5, 6 Brooke Worster, 7 Mary Naylor, 1, 2 Jesse Chittams, 1 Martin Cheatle 8 1 Department of Biobehavioral Health Sciences, NewCourtland Center for Transitions and Health, School of Nursing, University of Pennsylvania, Philadelphia, PA, USA; 2 Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA, USA; 3 Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 4 Department of Psychology, State University of New York at Buffalo, Buffalo, NY, USA; 5 Department of Community and Health Systems, School of Nursing, Indiana University, Indianapolis, IN, USA; 6 Center for Aging Research, Regenstrief Institute, Indianapolis, IN, USA; 7 Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA; 8 Department of Psychiatry and Anesthesiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Correspondence: Salimah H Meghani Department of Biobehavioral Health Sciences, NewCourtland Center for Transitions and Health, Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA, USA Tel +215 573-7128 Email Introduction: Based on many published reports, African American patients with cancer experience higher pain severity scores and lower pain relief than White patients. This disparity results from undertreatment of pain and is compounded by low adherence to prescribed non-opioid and opioid analgesics among African American patients with cancer. While nearly one in four patients use cannabis to manage cancer-related symptoms, less is known about how cannabis use influences pain relief in this patient population. Methods: This study is based on preliminary data from an ongoing study of longitudinal outcomes of opioid therapy among African American and White patients with cancer. Linear mixed-effects models were utilized to assess the interaction of race and cannabis use on pain relief using "least pain" item scores from the Brief Pain Inventory (BPI) averaged across three time points. Models were adjusted for sociodemographic and clinical variables. Results: This analysis included 136 patients (49 African American, 87 White). Overall, 30.1% of the sample reported cannabis use for cancer pain. The mean "least pain" score on BPI was 3.3 (SD=2.42) on a scale of 0– 10. African American patients had a mean "least pain" score 1.32± 0.48 units higher (indicating lower pain relief) than White patients ( p =0.006). Cannabis use did not have a significant main effect ( p =0.28). However, cannabis use was a significant moderator of the relationship between race and "least pain" ( p =0.03). In the absence of cannabis use, African Americans reported higher "least pain" scores compared to Whites (mean difference=1.631± 0.5, p =0.001). However, this disparity was no longer observed in African American patients reporting cannabis use (mean "least pain" difference=0.587± 0.59, p =0.32). Conclusion: These findings point to the possible role of cannabis in cancer pain management and its potential to reduce racial disparities. These findings are preliminary and further research into the role of cannabis in cancer pain outcomes is needed. Keywords: pain, cancer pain, pain relief, pain disparities, cannabis Unrelieved pain is an issue of significant magnitude across the trajectory of cancer; however, the burden is disproportionate for some groups. One of the most consistent findings on pain treatment disparities pertain to African Americans as identified in key national reports 1 and other systematic reviews. 2,3 A meta-analysis synthesizing 20 years of published research in the United States suggests that African American patients have the highest risk of pain undertreatment than any other racial and ethnic subgroup, regardless of the diagnosis. 4 While both Whites and African American patients report significant cancer-related pain across a number of studies, 5–8 African American patients report a clinically meaningful 9 higher level of pain scores—an indicator of inadequate pain relief. Stark disparities also have been found between African Americans and Whites in their use of prescribed non-opioid and opioid analgesics for cancer pain. 10 In one study, adherence to scheduled opioids (ie, percentage of the total number of prescribed doses taken) was only 57% for African Am -Abstract Truncated-
clinical neurology